泌尿生殖器がん患者における免疫チェックポイント阻害剤誘発性下痢または大腸炎の治療における糞便微生物叢移植
泌尿生殖器がん患者における免疫チェックポイント阻害剤誘発性下痢/大腸炎に対する糞便微生物叢移植(FMT)
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
- To assess the safety and tolerability of fecal microbiota transplantation (FMT).
- To assess the efficacy of FMT for clinical remission/response of immune-related diarrhea/colitis.
SECONDARY OBJECTIVES:
- To measure the recurrence rate after achieving clinical remission/response of immune-related diarrhea/colitis.
EXPLORATORY OBJECTIVES:
- To assess the efficacy of FMT to achieve endoscopic remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT to achieve histological remission of immune-related diarrhea/colitis.
- To assess the efficacy of FMT on recurrence of immune-related diarrhea/colitis after resumption of immune checkpoint inhibitors (ICPI).
- To assess immunological, molecular and microbiome changes in tissue/blood/stool.
To study the efficacy and/ or benefit of PuraStat gel in the healing of mucosal ulcers and its hemostatic effect on bleeding lesions
OUTLINE:
Patients receive loperamide orally (PO). After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
After completion of study treatment, patients are followed up at 2, 4, and 8 weeks, and then at 3 months.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Yinghong Wang
- 電話番号:281-221-9138
- メール:ywang59@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- M D Anderson Cancer Center
-
主任研究者:
- Yinghong Wang
-
コンタクト:
- Yinghong Wang
- 電話番号:713-792-7672
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of any type of genitourinary (kidney, bladder and prostate), melanoma, non-melanoma skin cancer, lung, head & neck, sarcoma/lymphoma, gastrointestinal system (luminal GI, hepatobiliary, pancreas), gynecology system (ovarian, uterine, cervical), and breast malignancies
- Treatment with any ICPI agent(s)
- Participants with new onset of ≥ grade 2 ICPI-induced diarrhea and/or colitis symptoms based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5 within 45 days prior to date of FMT treatment without involvement of non- GI toxicity
- Participants with a history of steroid use before FMT can be allowed if last dose was > 30 days prior to FMT treatment or treatment duration was for <7 days beyond one week prior to FMT treatment
- Participants with a history of immunosuppressant (Infliximab, Vedolizumab etc) use before FMT can be allowed if last dose was administered ≥ 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., Infliximab is used in the treatment of Crohn's disease, rheumatoid arthritis, plaque psoriasis, and Vedolizumab is used in treating ulcerative colitis)
- No concern for active concomitant GI infection at the time of initiation of protocol therapy as confirmed by stool tests or as per the treating physician based on clinical presentation
- Patient has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g., lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of protocol therapy and/ or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy
- Ability to understand and willingness to sign an informed consent form
- Life expectancy > 6 months
Exclusion Criteria
- Age younger than 18 years
- Participants with persistent GI infection confirmed with positive stool test(s) despite completing 5 days of antibiotics prior to initiation of protocol therapy
- History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
- Pregnant and breastfeeding women
- Women who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that participant is peri- or post-menopausal or there has been recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment
- Immunosuppressive treatment at onset of ICPI-induced diarrhea/colitis
- Any medical conditions (e.g. severe heart failure, brain hemorrhage, septic shock, etc.) that are high risk for colonoscopy procedure by the assessment of the study PI or Co-PIs.
- Participants who develop concurrent non-GI toxicity at the time of study treatment
- Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (loperamide, colonoscopy, FMT)
Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes. |
Undergo FMT via colonoscopy
他の名前:
Given PO |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of fecal microbiota transplantation (FMT)-related adverse events
時間枠:Up to 3 months post-FMT
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5. All events are recorded with grade and attribution to FMT. |
Up to 3 months post-FMT
|
|
Clinical response/remission of immune-related diarrhea/colitis
時間枠:At 2 weeks post-FMT
|
Clinical remission of immune related events defined as improvement of symptoms of grade 1 or lower within 2 weeks post-FMT. Clinical partial response of immune related diarrhea/colitis defined as improvement of diarrhea/colitis to a lower grade than the initial presentation but not meeting criteria of clinical remission at 2 week post-FMT time point. |
At 2 weeks post-FMT
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response
時間枠:Up to 3 months post-FMT
|
Recurrent immune-related diarrhea colitis events occurring post-FMT are recorded throughout the follow-up period. |
Up to 3 months post-FMT
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Endoscopic remission (Mayo Clinic sub-score 0-1) of immune-related diarrhea/colitis
時間枠:At 4 weeks and 8 weeks post-FMT
|
Endoscopic remission is defined as Mayo Clinic endoscopic subscore 0 or 1 (absence of ulcers, with or without mild erythema, friability and decreased vascular pattern). |
At 4 weeks and 8 weeks post-FMT
|
|
Histological remission (resolution of active inflammation) of immune-related diarrhea/colitis
時間枠:At 8 weeks post-FMT
|
Histological remission is defined resolution of active inflammation on biopsy sample. |
At 8 weeks post-FMT
|
|
Recurrent immune-related diarrhea/colitis following FMT and immune checkpoint inhibitors (ICPI) resumption within 6 months of ICPI resumption
時間枠:Up to 6 months after restarting ICPI
|
Recurrent immune-related diarrhea colitis events occurring post-FMT will be recorded throughout the follow-up period. |
Up to 6 months after restarting ICPI
|
|
Measure immunological measures (including levels of cytokines (IL-6, 17, TNF, etc.) in tissue/blood/stool samples
時間枠:Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include levels of cytokines (IL-6, 17, TNF, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
|
Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples
時間枠:Up to 3 months
|
Blood, stool, and colon tissues will be collected from at each scheduled time point. Markers of interest for immunological and biological profiles include frequencies of immune cells (CD4/8 T cells, Treg, macrophages, etc). Special attention will focus on Bacteroidetes, Akkermansia, and Blautia. |
Up to 3 months
|
協力者と研究者
捜査官
- 主任研究者:Yinghong Wang、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 部位別新生物
- 新生物
- 男性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 兆候と症状、消化器
- 腸の病気
- 気道疾患
- 組織型別の新生物
- 消化器系疾患
- 消化器疾患
- 子宮の病気
- 生殖器疾患、女性
- 肺疾患
- 内分泌腺腫瘍
- 気道腫瘍
- 胸部腫瘍
- 結腸疾患
- 卵巣疾患
- 付属器疾患
- 性器腫瘍、女性
- 性腺疾患
- 皮膚疾患
- 胃腸炎
- 乳房の病気
- 子宮頸部疾患
- 神経外胚葉性腫瘍
- 新生物、生殖細胞および胚
- 新生物、神経組織
- 神経内分泌腫瘍
- 母斑とメラノーマ
- 皮膚腫瘍
- 病理学的状態、徴候および症状
- 皮膚および結合組織疾患
- 徴候と症状
- 肺新生物
- 卵巣腫瘍
- 大腸炎
- 乳房腫瘍
- 子宮頸部腫瘍
- メラノーマ
- 泌尿生殖器腫瘍
- 子宮腫瘍
- 下痢
- 複素環化化合物、1リング
- 複素環化化合物
- 治療
- ピペリジン
- 生物療法
- ロペラミド
- 糞便微生物叢移植
その他の研究ID番号
- 2018-0663
- 2018-0663 (その他の識別子:M D Anderson Cancer Center)
- NCI-2019-02660 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。